Atherosclerosis
Volume 205, Issue 1 , Pages 296-301 , July 2009

Omega-3 fatty acids improve postprandial lipaemia in patients with nephrotic range proteinuria

  • Samira Bell

      Affiliations

    • Renal Unit, Walton Building, Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 141 211 0570; fax: +44 141 211 4843.
    • ,
  • Josephine Cooney

      Affiliations

    • Department of Vascular Biochemistry, Glasgow Royal Infirmary Glasgow, United Kingdom
    • ,
  • Christopher J. Packard

      Affiliations

    • Department of Vascular Biochemistry, Glasgow Royal Infirmary Glasgow, United Kingdom
    • ,
  • Muriel Caslake

      Affiliations

    • Department of Vascular Biochemistry, Glasgow Royal Infirmary Glasgow, United Kingdom
    • ,
  • Christopher J. Deighan

      Affiliations

    • Renal Unit, Walton Building, Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF, United Kingdom

Received 1 July 2008 ,Revised 24 November 2008 ,Accepted 1 December 2008.

References 

  1. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473–485
  2. Ginsberg HN, Jones J, Blaner WS, et al. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol. 1995;15:1829–1838
  3. Groot PH, van Stiphout WA, Krauss XH, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb. 1991;11:653–662
  4. Meyer E, Westerveld HT, Ruyter-Meijstek FC, et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case–control study. Atherosclerosis. 1996;124:221–235
  5. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992;12:1336–1345
  6. Weintraub MS, Grosskopf I, Rassin T, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996;312:936–939
  7. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83–97
  8. Boquist S, Ruotolo G, Tang R, et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation. 1999;100:723–728
  9. Delawi D, Meijssen S, Castro CM. Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. Clin Chim Acta. 2003;328:139–145
  10. van Oostrom AJ, Castro CM, Ribalta J, et al. Diurnal triglyceride profiles in healthy normolipidemic male subjects are associated to insulin sensitivity, body composition and diet. Eur J Clin Invest. 2000;30:964–971
  11. Lewis GF, O’Meara NM, Soltys PA, et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab. 1991;72:934–944
  12. Halkes CJ, van Dijk H, de Jaegere PP, et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol. 2001;21:1526–1530
  13. Warwick GL, Packard CJ. Lipoprotein metabolism in the nephrotic syndrome. Nephrol Dial Transplant. 1993;8:385–396
  14. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis. 1994;23:331–346
  15. Davies RW, Staprans I, Hutchison FN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest. 1990;86:600–605
  16. Shearer GC, Stevenson FT, Atkinson DN, et al. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int. 2001;59:179–189
  17. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1. Kidney Int. 2000;58:1238–1246
  18. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S–1654S
  19. Sanders TA, Sullivan DR, Reeve J, Thompson GR. Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis. 1985;5:459–465
  20. Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest. 1984;74:82–89
  21. Harris WS, Connor WE, Alam N, Illingworth DR. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res. 1988;29:1451–1460
  22. Nozaki S, Garg A, Vega GL, Grundy SM. Postheparin lipolytic activity and plasma lipoprotein response to omega-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia. Am J Clin Nutr. 1991;53:638–642
  23. Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988;82:1884–1893
  24. Wang H, Chen X, Fisher EA. N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes. J Clin Invest. 1993;91:1380–1389
  25. Caslake MJ, Packard CJ. The use of ultracentrifugation for the separation of lipoproteins. In: Rifai , Warnick , Dominiczak  editor. Handbook of lipoprotein testing. AACC Press; 2000;p. 625–646
  26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  27. Levy E, Ziv E, Bar-On H, Shafrir E. Chylomicron synthesis in experimental nephrotic syndrome. Biochim Biophys Acta. 1989;1005:20–26
  28. Levy E, Ziv E, Bar-On H, Shafrir E. Experimental nephrotic syndrome: removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin. Biochim Biophys Acta. 1990;1043:259–266
  29. Warwick GL, Packard CJ, Stewart JP, et al. Post-prandial lipoprotein metabolism in nephrotic syndrome. Eur J Clin Invest. 1992;22:813–820
  30. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219
  31. Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis. 1998;138:229–235
  32. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis. 1993;22:135–142
  33. Roche HM, Gibney MJ. Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr. 2000;71:232S–237
  34. Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr. 2000;71:914–920
  35. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S–1654
  36. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455–463
  37. Rustan AC, Nossen JO, Christiansen EN, Drevon CA. Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme A: 1,2-diacylglycerol acyltransferase. J Lipid Res. 1988;29:1417–1426
  38. Marsh JB, Topping DL, Nestel PJ. Comparative effects of dietary fish oil and carbohydrate on plasma lipids and hepatic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rat. Biochim Biophys Acta. 1987;922:239–243

PII: S0021-9150(08)00844-7

doi: 10.1016/j.atherosclerosis.2008.12.002

Atherosclerosis
Volume 205, Issue 1 , Pages 296-301 , July 2009

Article Tools

* Image Usage & Resolution